[go: up one dir, main page]

WO2007146172A3 - Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same - Google Patents

Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same Download PDF

Info

Publication number
WO2007146172A3
WO2007146172A3 PCT/US2007/013587 US2007013587W WO2007146172A3 WO 2007146172 A3 WO2007146172 A3 WO 2007146172A3 US 2007013587 W US2007013587 W US 2007013587W WO 2007146172 A3 WO2007146172 A3 WO 2007146172A3
Authority
WO
WIPO (PCT)
Prior art keywords
epitope
cancer cells
methods
same
expressed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/013587
Other languages
French (fr)
Other versions
WO2007146172A8 (en
WO2007146172A2 (en
Inventor
Rong-Hwa Lin
Leewen Lin
Shih-Yao Lin
Shu-Hua Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abgenomics Corp
Original Assignee
Abgenomics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ572561A priority Critical patent/NZ572561A/en
Priority to CA2652703A priority patent/CA2652703C/en
Priority to EP07795937.7A priority patent/EP2044120B1/en
Priority to ES07795937T priority patent/ES2718952T3/en
Priority to CN2007800210173A priority patent/CN101516912B/en
Priority to BRPI0712850A priority patent/BRPI0712850A8/en
Priority to DK07795937.7T priority patent/DK2044120T3/en
Priority to KR1020147009345A priority patent/KR101510753B1/en
Priority to MX2008015049A priority patent/MX2008015049A/en
Priority to PCT/US2007/013587 priority patent/WO2007146172A2/en
Priority to AU2007258473A priority patent/AU2007258473B2/en
Application filed by Abgenomics Corp filed Critical Abgenomics Corp
Priority to JP2009514412A priority patent/JP5313886B2/en
Priority to KR1020087029660A priority patent/KR101496433B1/en
Publication of WO2007146172A2 publication Critical patent/WO2007146172A2/en
Publication of WO2007146172A3 publication Critical patent/WO2007146172A3/en
Priority to IL195098A priority patent/IL195098B/en
Priority to ZA2008/09535A priority patent/ZA200809535B/en
Anticipated expiration legal-status Critical
Publication of WO2007146172A8 publication Critical patent/WO2007146172A8/en
Priority to IL242653A priority patent/IL242653B/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention provides novel antibodies specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells, but do not specifically bind to a CD43 expressed by a leukocyte or by a Jurkat cell, and is capable of inducing apoptosis of the nonhematopoietic cancer cell after binding to the epitope on cell surface of the nonhematopoietic cancer cell in the absence of cytotoxin conjugation and immune effector function, wherein the epitope comprises a carbohydrate structure and the binding of the antibody to the epitope is inhibited by a carbohydrate comprising a Leastructure, a Lea-lactose structure, a LNDFH II structure, or a LNT structure. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.
PCT/US2007/013587 2006-06-07 2007-06-07 Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same Ceased WO2007146172A2 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
AU2007258473A AU2007258473B2 (en) 2006-06-07 2007-06-07 Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
EP07795937.7A EP2044120B1 (en) 2006-06-07 2007-06-07 Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
ES07795937T ES2718952T3 (en) 2006-06-07 2007-06-07 Antibodies that recognize an epitope that contains carbohydrates on CD-43 and CEA expressed in cancer cells and methods that use them
CN2007800210173A CN101516912B (en) 2006-06-07 2007-06-07 Antibodies recognizing sugar-containing epitopes of CD-43 and CEA expressed on cancer cells and methods of use thereof
BRPI0712850A BRPI0712850A8 (en) 2006-06-07 2007-06-07 antibodies that recognize a cd-43 and cea carbohydrate-containing epitope expressed in cancer cells and methods of using them
DK07795937.7T DK2044120T3 (en) 2006-06-07 2007-06-07 ANTIBODIES THAT RECOGNIZE A CARBOHYDRATE-CONTAINING EPITOP ON CD-43 AND CEA EXPRESSED ON CANCER CELLS, AND METHODS FOR USING IT
KR1020147009345A KR101510753B1 (en) 2006-06-07 2007-06-07 Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
MX2008015049A MX2008015049A (en) 2006-06-07 2007-06-07 Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same.
JP2009514412A JP5313886B2 (en) 2006-06-07 2007-06-07 Antibodies that recognize carbohydrate-containing epitopes of CD-43 and CEA expressed in cancer cells and methods of using the same
NZ572561A NZ572561A (en) 2006-06-07 2007-06-07 Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
CA2652703A CA2652703C (en) 2006-06-07 2007-06-07 Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
PCT/US2007/013587 WO2007146172A2 (en) 2006-06-07 2007-06-07 Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
KR1020087029660A KR101496433B1 (en) 2006-06-07 2007-06-07 Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
IL195098A IL195098B (en) 2006-06-07 2008-11-04 Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
ZA2008/09535A ZA200809535B (en) 2006-06-07 2008-11-07 Antibodies recognozing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
IL242653A IL242653B (en) 2006-06-07 2015-11-18 Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81185006P 2006-06-07 2006-06-07
US60/811,850 2006-06-07
PCT/US2007/013587 WO2007146172A2 (en) 2006-06-07 2007-06-07 Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same

Publications (3)

Publication Number Publication Date
WO2007146172A2 WO2007146172A2 (en) 2007-12-21
WO2007146172A3 true WO2007146172A3 (en) 2008-05-08
WO2007146172A8 WO2007146172A8 (en) 2009-04-23

Family

ID=38832425

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/013587 Ceased WO2007146172A2 (en) 2006-06-07 2007-06-07 Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same

Country Status (19)

Country Link
US (4) US7674605B2 (en)
EP (1) EP2044120B1 (en)
JP (4) JP5313886B2 (en)
KR (2) KR101510753B1 (en)
CN (2) CN101516912B (en)
AU (1) AU2007258473B2 (en)
BR (1) BRPI0712850A8 (en)
CA (1) CA2652703C (en)
DK (1) DK2044120T3 (en)
ES (1) ES2718952T3 (en)
HU (1) HUE043255T2 (en)
IL (2) IL195098B (en)
MX (1) MX2008015049A (en)
NZ (1) NZ572561A (en)
RU (2) RU2461572C2 (en)
SG (2) SG10201604649SA (en)
TW (1) TWI429658B (en)
WO (1) WO2007146172A2 (en)
ZA (1) ZA200809535B (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7982017B2 (en) 2007-12-18 2011-07-19 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
US9089614B2 (en) 2012-12-21 2015-07-28 Bioalliance C.V. Hydrophilic self-immolative linkers and conjugates thereof
US9193794B2 (en) 2006-06-07 2015-11-24 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
US9950077B2 (en) 2014-06-20 2018-04-24 Bioalliance C.V. Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof
US10472422B2 (en) 2016-01-08 2019-11-12 Abgenomics International Inc. Tetravalent anti-PSGL-1 antibodies and uses thereof
US12290565B2 (en) 2021-11-17 2025-05-06 Altrubio Inc. Methods of using anti-PSGL-1 antibodies in combination with JAK inhibitors to treat T-cell mediated inflammatory diseases or cancers

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110372795A (en) 2007-08-02 2019-10-25 吉利德生物制剂公司 LOX and LOXL2 inhibitor and its application
WO2010080769A2 (en) 2009-01-06 2010-07-15 Arresto Biosciences, Inc. Chemotherapeutic methods and compositions
CN102549012B (en) 2009-05-07 2015-07-01 诺维信生物制药丹麦公司 Process for purifying albumin
EP2427488A1 (en) * 2009-05-07 2012-03-14 Novozymes Biopharma DK A/S Method of controlling o-linked glycosylation of antibodies
US8784819B2 (en) * 2009-09-29 2014-07-22 Ibio Inc. Influenza hemagglutinin antibodies, compositions and related methods
CA2803937A1 (en) * 2010-06-30 2012-01-05 Mount Sinai Hospital Reagents and methods for diagnosing conditions associated with hydroxylated hif 1-a
JP5315495B2 (en) 2010-09-28 2013-10-16 積水化学工業株式会社 Anti-human CCR7 antibody, hybridoma, nucleic acid, vector, cell, pharmaceutical composition, and antibody-immobilized carrier
KR101364172B1 (en) * 2011-01-12 2014-02-17 서울대학교산학협력단 Monoclonal antibody to specific monkey CD43 and a hybridoma producing the same
US8852592B2 (en) 2011-05-10 2014-10-07 Biocare Medical, Llc Systems and methods for anti-PAX8 antibodies
ES2741936T3 (en) 2012-02-24 2020-02-12 Abbvie Stemcentrx Llc Anti-SEZ6 antibodies and use procedures
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
EP2834641A1 (en) 2012-04-02 2015-02-11 Gundersen Lutheran Health Systems, Inc. Reagents, methods, and kits for the classification of cancer
US9429577B2 (en) 2012-09-27 2016-08-30 Biocare Medical, Llc Anti-uroplakin II antibodies systems and methods
HUE045435T2 (en) 2012-10-12 2019-12-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
US10429390B2 (en) 2012-12-18 2019-10-01 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
EP2962113B1 (en) 2013-02-28 2019-04-03 Biocare Medical, LLC Anti-p40 antibodies systems and methods
JP6444902B2 (en) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ Pyrrolobenzodiazepine and its conjugates
DK3052522T3 (en) 2013-10-03 2020-02-24 Biocare Medical Llc ANTI-SOX 10 ANTIBODY SYSTEMS AND PROCEDURES
ES2729057T3 (en) 2013-12-17 2019-10-30 Aimm Therapeutics Bv Means and methods to counteract myeloproliferative or lymphoproliferative disorders
WO2016026143A1 (en) * 2014-08-22 2016-02-25 Huiru Wang Saccharide-based biomarkers and therapeutics
JP6531166B2 (en) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ Pyrrolobenzodiazepine and its conjugate
UY36449A (en) 2014-12-19 2016-07-29 Novartis Ag COMPOSITIONS AND METHODS FOR ANTIBODIES DIRECTED TO BMP6
CA2989551A1 (en) 2015-06-24 2016-12-29 Aimm Therapeutics B.V. Aml antigens and uses thereof
CA3001676C (en) * 2015-10-12 2022-12-06 Aprogen Kic Inc. Anti-cd43 antibody and use thereof for cancer treatment
CN110381988A (en) 2016-06-15 2019-10-25 诺华股份有限公司 Methods of treating diseases using inhibitors of bone morphogenetic protein 6 (BMP6)
CN107663240B (en) * 2016-07-29 2021-01-12 中国人民解放军第四军医大学 Single-chain antibody specifically bound by highly glycosylated CEA and application thereof in detection and treatment
JP2019534882A (en) 2016-10-11 2019-12-05 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ Antibody-drug conjugates with immune-mediated therapeutics
WO2018071718A1 (en) 2016-10-14 2018-04-19 Nima Labs, Inc. Anti-gliadin antibodies
EA201991204A1 (en) 2016-12-22 2019-12-30 Университа Дельи Студи Манья Греча Катандзаро MONOCLONAL ANTIBODY AGAINST UNIQUE Sialoglycosylated Tumor-Associated Epitope CD43
CN108753733B (en) * 2018-04-11 2022-03-25 南京泰斯德生物科技有限公司 Hybridoma cell strain, anti-glycosyl monoclonal antibody generated by hybridoma cell strain, preparation method and preparation
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN110922485B (en) * 2019-12-13 2021-11-19 福州迈新生物技术开发有限公司 anti-Ep-cam protein monoclonal antibody, cell line, preparation method and application thereof
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CA3236930A1 (en) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
CN114778857B (en) 2022-06-17 2022-08-23 信纳克(北京)生化标志物检测医学研究有限责任公司 Reagent composition for detecting nonhematopoietic tumor and application thereof
US12060148B2 (en) 2022-08-16 2024-08-13 Honeywell International Inc. Ground resonance detection and warning system and method
CN115814091B (en) * 2022-12-19 2024-08-09 中山大学 Use of CD43 inhibitor in preparation of anti-colorectal tumor drugs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0528767A1 (en) * 1991-08-21 1993-02-24 Sandoz Ltd. Antibody derivatives

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
FR2413974A1 (en) 1978-01-06 1979-08-03 David Bernard DRYER FOR SCREEN-PRINTED SHEETS
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US6808901B1 (en) 1984-09-03 2004-10-26 Celltech R&D Limited Production of chimeric antibodies
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
JP3040121B2 (en) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド Methods of treating tumor cells by inhibiting growth factor receptor function
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5356817A (en) * 1988-06-09 1994-10-18 Yale University Methods for detecting the onset, progression and regression of gynecologic cancers
AU631802B2 (en) 1988-06-14 1992-12-10 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0454781B1 (en) 1989-01-23 1998-12-16 Chiron Corporation Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE69034168T3 (en) 1989-03-21 2013-04-11 Vical, Inc. Expression of exogenous polynucleotide sequences in vertebrates
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
ATE144793T1 (en) 1989-06-29 1996-11-15 Medarex Inc BISPECIFIC REAGENTS FOR AIDS THERAPY
EP1645635A3 (en) 1989-08-18 2010-07-07 Oxford Biomedica (UK) Limited Replication defective recombinant retroviruses expressing a palliative
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
KR0162259B1 (en) 1989-12-05 1998-12-01 아미 펙터 Chimeric Antibodies for Detection and Treatment of Infectious and Inflammatory Lesions
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
WO1991014438A1 (en) 1990-03-20 1991-10-03 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
NZ237464A (en) 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (en) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE218889T1 (en) 1990-11-09 2002-06-15 Stephen D Gillies CYTOKINE IMMUNOCONJUGATES
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
DE69233013T2 (en) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer ADENOVIRUS MEDIATED GENTRANSFER INTO THE GASTROINTESTINAL TRACT
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
JP3540315B2 (en) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル Production of Chimeric Antibodies-Combination Approach
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
AU3144193A (en) 1991-11-21 1993-06-15 Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
FR2688514A1 (en) 1992-03-16 1993-09-17 Centre Nat Rech Scient Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JPH07507689A (en) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Specific tissue targeting methods and compositions
JPH09507741A (en) 1992-06-10 1997-08-12 アメリカ合衆国 Vector particles resistant to inactivation by human serum
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
ATE149570T1 (en) 1992-08-17 1997-03-15 Genentech Inc BISPECIFIC IMMUNOADHESINS
CA2592997A1 (en) 1992-12-03 1994-06-09 Genzyme Corporation Pseudo-adenovirus vectors
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
AU6818094A (en) 1993-04-22 1994-11-08 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
JP3532566B2 (en) 1993-06-24 2004-05-31 エル． グラハム，フランク Adenovirus vectors for gene therapy
EP0694070B1 (en) 1993-09-15 2002-04-10 Chiron Corporation Recombinant alphavirus vectors
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
JP3875990B2 (en) 1993-10-25 2007-01-31 カンジ，インコーポレイテッド Recombinant adenoviral vectors and methods of use
NZ276305A (en) 1993-11-16 1997-10-24 Depotech Corp Controlled release vesicle compositions
US6436908B1 (en) 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
WO1995030763A2 (en) 1994-05-09 1995-11-16 Chiron Viagene, Inc. Retroviral vectors having a reduced recombination rate
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
AU2998597A (en) 1996-05-06 1997-11-26 Chiron Corporation Crossless retroviral vectors
US6048703A (en) 1996-11-15 2000-04-11 Cephalon, Inc. Methods for detecting cell apoptosis
JP2001523977A (en) 1997-06-05 2001-11-27 ザ ユニバーシティ オブ テキサス システム ボード オブ リージェンツ Activator of APAF-1, CED-4 human homolog, caspase-3
AU9692198A (en) 1997-10-10 1999-05-03 Kevin J. Donahue Gene delivery compositions and methods
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
IL129299A0 (en) * 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
SE0000597D0 (en) * 2000-02-24 2000-02-24 Active Biotech Ab Novel antibody
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2002101071A2 (en) 2001-06-07 2002-12-19 Rigel Pharmaceuticals, Inc. Cd43:modulators of mast cell degranulation
US20040018557A1 (en) 2002-03-01 2004-01-29 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
WO2003074679A2 (en) 2002-03-01 2003-09-12 Xencor Antibody optimization
CU23228A1 (en) 2002-04-29 2007-09-26 Ct Ingenieria Genetica Biotech FRAGMENTS OF SPECIFIC ANTIBODIES FOR THE HUMAN CARCINOEMBRIONARY ANTIGEN (CEA) SEQUENCES OF ITS VARIABLE REGIONS AND VECTORS FOR THE MICROBIAL EXPRESSION OF THE SAME
EP1782838A4 (en) 2004-06-23 2007-08-01 Japan Science & Tech Agency INHIBITION OF INFILTRATION AND AGENT TAKING CELLS
AU2005316844A1 (en) 2004-11-29 2006-06-22 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
WO2007048022A2 (en) 2005-10-21 2007-04-26 Alexion Pharmaceuticals, Inc. Antibody-polypeptide fusion proteins and methods for producing and using same
DK2044120T3 (en) 2006-06-07 2019-04-15 Bioalliance Cv ANTIBODIES THAT RECOGNIZE A CARBOHYDRATE-CONTAINING EPITOP ON CD-43 AND CEA EXPRESSED ON CANCER CELLS, AND METHODS FOR USING IT
AU2008338313B2 (en) 2007-12-18 2014-01-16 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
US7982934B2 (en) * 2009-09-09 2011-07-19 Microvision, Inc. Scanned beam display with parallelogram distortion correction

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0528767A1 (en) * 1991-08-21 1993-02-24 Sandoz Ltd. Antibody derivatives

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BAECKSTROM DAN ET AL: "Expression of the leukocyte-associated sialoglycoprotein CD43 by a colon carcinoma cell line", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 23, 1995, pages 13688 - 13692, XP002471811, ISSN: 0021-9258 *
FERNANDEZ-RODRIGUEZ J ET AL: "The leukocyte antigen CD43 is expressed in different cell lines of nonhematopoietic origin", TUMOR BIOLOGY, KARGER, BASEL, CH, vol. 23, no. 4, 2002, pages 193 - 201, XP008087563, ISSN: 1010-4283 *
PIMENIDOU APOSTOLIA ET AL: "Novel CD43 specific phage antibodies react with early stage colorectal tumours", ONCOLOGY REPORTS, NATIONAL HELLENIC RESEARCH FOUNDATION, ATHENS, GR, vol. 11, no. 2, February 2004 (2004-02-01), pages 327 - 331, XP009096837, ISSN: 1021-335X *
SANTAMARIA MANUEL ET AL: "Specific monoclonal antibodies against leukocyte-restricted cell surface molecule CD43 react with nonhematopoietic tumor cells", CANCER RESEARCH, vol. 56, no. 15, 1996, pages 3526 - 3529, XP002471809, ISSN: 0008-5472 *
SIKUT REIN ET AL: "Detection of CD43 (leukosialin) in colon adenoma and adenocarcinoma by novel monoclonal antibodies against its intracellular domain", INTERNATIONAL JOURNAL OF CANCER, vol. 82, no. 1, 2 July 1999 (1999-07-02), pages 52 - 58, XP002471810, ISSN: 0020-7136 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9193794B2 (en) 2006-06-07 2015-11-24 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
US7982017B2 (en) 2007-12-18 2011-07-19 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
US8568718B2 (en) 2007-12-18 2013-10-29 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
US9334329B2 (en) 2007-12-18 2016-05-10 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
US9089614B2 (en) 2012-12-21 2015-07-28 Bioalliance C.V. Hydrophilic self-immolative linkers and conjugates thereof
US9408923B2 (en) 2012-12-21 2016-08-09 Bioalliance C.V. Hydrophilic self-immolative linkers and conjugates thereof
US9943610B2 (en) 2012-12-21 2018-04-17 Bioalliance C.V. Hydrophilic self-immolative linkers and conjugates thereof
US9950077B2 (en) 2014-06-20 2018-04-24 Bioalliance C.V. Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof
US10472422B2 (en) 2016-01-08 2019-11-12 Abgenomics International Inc. Tetravalent anti-PSGL-1 antibodies and uses thereof
US12290565B2 (en) 2021-11-17 2025-05-06 Altrubio Inc. Methods of using anti-PSGL-1 antibodies in combination with JAK inhibitors to treat T-cell mediated inflammatory diseases or cancers

Also Published As

Publication number Publication date
JP2013231055A (en) 2013-11-14
KR101510753B1 (en) 2015-04-10
RU2616868C2 (en) 2017-04-18
US7674605B2 (en) 2010-03-09
RU2461572C2 (en) 2012-09-20
IL195098B (en) 2018-01-31
MX2008015049A (en) 2009-02-16
CN103709252A (en) 2014-04-09
KR20140047176A (en) 2014-04-21
KR20090057172A (en) 2009-06-04
HUE043255T2 (en) 2019-08-28
US9193794B2 (en) 2015-11-24
IL195098A0 (en) 2011-08-01
TWI429658B (en) 2014-03-11
US20080171043A1 (en) 2008-07-17
JP2017114905A (en) 2017-06-29
BRPI0712850A8 (en) 2018-05-02
NZ572561A (en) 2012-05-25
CN103709252B (en) 2016-12-07
US20180238895A1 (en) 2018-08-23
IL242653B (en) 2018-01-31
JP5313886B2 (en) 2013-10-09
WO2007146172A8 (en) 2009-04-23
JP6145142B2 (en) 2017-06-07
ES2718952T3 (en) 2019-07-05
AU2007258473B2 (en) 2012-08-23
DK2044120T3 (en) 2019-04-15
AU2007258473A1 (en) 2007-12-21
WO2007146172A2 (en) 2007-12-21
JP2009539380A (en) 2009-11-19
ZA200809535B (en) 2010-02-24
SG172684A1 (en) 2011-07-28
CN101516912A (en) 2009-08-26
CA2652703A1 (en) 2007-12-21
JP2016029048A (en) 2016-03-03
BRPI0712850A2 (en) 2012-08-14
CA2652703C (en) 2018-08-28
CN101516912B (en) 2013-10-30
RU2008152332A (en) 2010-07-27
US20160139131A1 (en) 2016-05-19
SG10201604649SA (en) 2016-07-28
US20100124551A1 (en) 2010-05-20
KR101496433B1 (en) 2015-02-26
EP2044120A2 (en) 2009-04-08
EP2044120B1 (en) 2019-01-30
RU2012121875A (en) 2013-11-27
TW200815473A (en) 2008-04-01

Similar Documents

Publication Publication Date Title
WO2007146172A3 (en) Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
WO2009014708A3 (en) Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
WO2009033094A3 (en) Antibodies and related molecules that bind to 24p4c12 proteins
NZ600143A (en) Therapeutic applications of activation of human antigen-presenting cells through dectin-1
PL367831A1 (en) Recombinant tumor specific antibody and use thereof
WO2008085562A3 (en) Combinatorieal therapy of cancer and infectious diseases with anti-b7-h1 antibodies
WO2002020039A3 (en) Use of trifunctional bispecific and trispecific antibodies for the treatment of malignant ascites
WO2009051220A1 (en) Antibody capable of specifically binding to aβ oligomer, and use thereof
WO2005103081A3 (en) Human monoclonal antibodies against cd20
WO2006099141A3 (en) Anti-mesothelin antibodies
EA201070463A1 (en) COMBINED THERAPY WITH THE USE OF ANTIBODY AND MEDICINE CONJUGATES
NZ602220A (en) Antibodies with ph dependent antigen binding
FI1897548T4 (en) T cell regulation
MX2010006213A (en) Method of inhibition of leukemic stem cells.
WO2003072036A3 (en) Treatment methods using anti-cd22 antibodies
WO2004091657A3 (en) Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
WO2009004822A1 (en) ANTI-Muc17 ANTIBODY
WO2008118733A3 (en) Methods of treating cancer by administering human il-18 combinations
GB2462048A (en) Antibodies binding to an intracellular prl-1 or prl-3 polypeptide
WO2003089593A3 (en) Adjuvant enhanced immunotherapy
WO2006108670A3 (en) Use of cd25 antibodies in immunotherapy
WO2008151819A3 (en) Treatment of tumors using specific anti-l1 antibody
BRPI0407680A (en) methods for cancer diagnosis and cancer cell metastasis reduction
WO2005072479A3 (en) Polymer-bound antibody concer therapeutic agent
WO2006105488A3 (en) Antibodies and related molecules that bind to 161p2f10b proteins

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780021017.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07795937

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007258473

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 572561

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 4514/KOLNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2652703

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2007258473

Country of ref document: AU

Date of ref document: 20070608

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2008/015049

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020087029660

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2009514412

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2007795937

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008152332

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0712850

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20081204

WWE Wipo information: entry into national phase

Ref document number: 1020147009345

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 242653

Country of ref document: IL